CXCR4-Targeting Metal-Nuclide Complexes for Tumor Imaging and Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective medicaments for diagnosing or treating diseases related to the overexpression of CXCR4, such as cancers and cardiovascular diseases, due to insufficient binding affinity and specificity to the CXCR4 receptor.
Innovation Solution
A novel complex comprising a metal nuclide-labeled compound that binds specifically to CXCR4, enhancing diagnostic and therapeutic efficacy through improved binding energy and specificity, and can be used for SPECT/PET imaging or MRI contrast.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CXCR4 ligands are used, then basic binding function is achieved, but binding affinity and specificity are insufficient
Solution Approach 1:
The patent applies composite materials by combining a CXCR4 ligand with a chelator moiety and a metal nuclide to create a multifunctional complex. This composite structure simultaneously achieves high binding affinity to CXCR4 receptors and provides enhanced imaging/therapeutic capabilities through the metal nuclide, directly resolving the contradiction between binding reliability and tumor aggregation capability
Solution Approach 2:
The patent employs parameter changes by incorporating metal nuclides (radioactive or non-radioactive) into the CXCR4 ligand complex. This modification changes the physical and chemical parameters of the original ligand, transforming it from a simple binding molecule to a multifunctional agent with improved tumor aggregation, imaging contrast, and therapeutic potential
2Reliability
If no metal nuclide is labeled, then结构简单 (structure is simple), but diagnostic and therapeutic efficacy are insufficient
Solution Approach 1:
The patent applies universality by designing a complex that performs multiple functions simultaneously: CXCR4 binding, tumor targeting, diagnostic imaging (via radioactive or non-radioactive metal nuclides), and potential therapy. This multifunctional design resolves the contradiction by making the complex structure serve multiple purposes, justifying its increased complexity through enhanced efficacy
Solution Approach 2:
The metal nuclide acts as an intermediary that bridges the CXCR4 ligand with diagnostic and therapeutic functions. The chelator moiety serves as another intermediary that stabilizes the metal nuclide while maintaining ligand binding capability. These intermediary components enable the transition from a simple ligand to a multifunctional agent with improved efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complex demonstrates enhanced binding to CXCR4-expressing cells, allowing for effective diagnosis and treatment of various diseases, including cancers and inflammatory diseases, with higher tumor aggregation and improved sensitivity.
Implementation Method 1
the radioactive metal nuclide is indium-111, lutetium-177, gallium-68, gallium-67, yttrium-90 or copper-64
Implementation Method 2
a non-radioactive metal ion is gadolinium or the like
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed herein is a complex, a contrast agent and the method for treating a disease related to CXCR4 receptor. The complex is configured to bind the CXCR4 receptor, and is used as a medicament for diagnosis and treatment of cancers and other indications related to the CXCR4 receptor.